Menu Search
Equities

Recce Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
R9Q:MUN

Recce Pharmaceuticals Ltd

Actions
  • Price (EUR)0.362
  • Today's Change0.000 / 0.00%
  • Shares traded5.00k
  • 1 Year change+25.69%
  • Beta0.1304
Data delayed at least 15 minutes, as of Feb 11 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance.

  • Revenue in AUD (TTM)7.70m
  • Net income in AUD-21.43m
  • Incorporated2007
  • Employees--
  • Location
    Recce Pharmaceuticals LtdLevel 23180 George St, Salesforce TowerSYDNEY 2000AustraliaAUS
  • Phone+61 29000-1907
  • Fax+61 28075-4584
  • Websitehttps://www.recce.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.